REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -1.61.

EBIT: As of FY2025 Q3, the actual value is USD -325.92 M.

Segment Revenue

• Research and Development Expenses: $262.5 million for the three months ended September 30, 2025, compared to $151.8 million for the same period in 2024, representing a 73% increase. For the nine months ended September 30, 2025, expenses were $692.4 million, compared to $404.1 million in 2024, a 71% increase.

Operational Metrics

• Net Loss: $305.2 million for the three months ended September 30, 2025, compared to $156.3 million for the same period in 2024. For the nine months ended September 30, 2025, net loss was $766.4 million, compared to $405.5 million in 2024.
• General and Administrative Expenses: $52.8 million for the three months ended September 30, 2025, compared to $24.0 million for the same period in 2024, representing a 120% increase. For the nine months ended September 30, 2025, expenses were $128.4 million, compared to $69.1 million in 2024, an 86% increase.

Cash Flow

• Net Cash Used in Operating Activities: - $623.5 million for the nine months ended September 30, 2025, compared to - $419.1 million for the same period in 2024.
• Net Cash Provided by Investing Activities: $43.2 million for the nine months ended September 30, 2025, compared to - $161.5 million in 2024.
• Net Cash Provided by Financing Activities: $255.9 million for the nine months ended September 30, 2025, compared to $85.6 million in 2024.

Unique Metrics

• Liability Related to Sale of Future Royalties: $256.5 million as of September 30, 2025.

Future Outlook and Strategy

• Core Business Focus: The company is advancing a deep pipeline of RAS(ON) inhibitors, including daraxonrasib, elironrasib, and zoldonrasib, with plans to initiate several Phase 3 registrational trials in 2025 and 2026.
• Non-Core Business: The company has entered into collaborations with Tango Therapeutics, Summit Therapeutics, and others to explore combination therapies and novel treatment approaches.

Priority

• The company emphasizes the development of RAS(ON) inhibitors and plans to initiate multiple pivotal trials, including the RASolute 302 study and RASolve 301 study, with expected clinical readouts in 2026.